Tocilizumab Risk of Diverticulitis and GI Perforation
A French registry analysis compared the risk of diverticulitis and gastrointestinal perforation (GIP) in…
View Resource
JAK Inhibitors in Difficult Still’s Disease
A small retrospective study suggests that patients with difficult to treat adult-onset Still’s disease…
View Resource
Heavy Metal Rheumatology (9.23.2022)
Thanks to all of you for your kind comments and great reviews of our…
View Resource
ICYMI: LAVLI – A New Autoinflammatory Disorder
Editor’s note: This article originally appeared March 28, 2023, and is being shared again…
View Resource
Depression and RA (3.8.2024)
Dr. Jack Cush reviews the news, journal reports and regulatory approvals from the past…
View Resource
Rhapsody Study: IL-1 Inhibition in Recurrent Pericarditis
Recurrent pericarditis is a rare, probable autoinflammatory disorder mediated by interleukin-1 (IL-1); and is often…
View Resource
Not Still’s – Now What?
Your patient doesn’t meet criteria for Still’s disease (AOSD or sJIA), now what should…
View Resource
Great and Not So Great (9.30.2022)
Dr. Jack Cush reviews the news and journal reports from the past week on…
View Resource
EULAR/ACR Guidance on Haemophagocytic Lymphohistiocytosis/Macrophage Activation Syndrome
A EULAR/American College of Rheumatology task force has established evidence based, up-to-date guidance, and…
View Resource
Effective Treatments for Still's Disease
A systematic review of pharmacological treatments for adult-onset Still disease (AOSD) supports the efficacy…
View Resource